A lot of money has been wasted on pursuing so many indications with failed trials. It would have been better to do a a proper phase 2 trial on aGVHD, demonstrate efficacy and then a proper phase 3 RCT trial that would have convinced the FDA. Once that was established with revenues choose another indication. The scatter gun failed phase 2 followed by failed phase 3 approach justified by "lots of biotechs lose a billion dollars get used to it" seems a bit cavalier.
CEO Itescu needs to go, page-270
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
0.000(0.00%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.08 | $5.380M | 4.893M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 69437 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 19999 | 1 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |